MedTech Acquisition (MedTech Acquisition) Operating Income : $-4.06 Mil (TTM As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is MedTech Acquisition Operating Income?

MedTech Acquisition's Operating Income for the three months ended in Jun. 2023 was $-1.43 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-4.06 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. MedTech Acquisition's Operating Income for the three months ended in Jun. 2023 was $-1.43 Mil. MedTech Acquisition's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, MedTech Acquisition's Operating Margin % for the quarter that ended in Jun. 2023 was %.

MedTech Acquisition's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MedTech Acquisition's annualized ROC % for the quarter that ended in Jun. 2023 was -30.94%. MedTech Acquisition's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was %.

MedTech Acquisition Operating Income Historical Data

The historical data trend for MedTech Acquisition's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedTech Acquisition Operating Income Chart

MedTech Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

Operating Income

-3.04

-2.75

MedTech Acquisition Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Operating Income	Get a 7-Day Free Trial							-0.29	-0.43	-1.36	-0.84	-1.43

MedTech Acquisition Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.06 Mil.

MedTech Acquisition (NAS:MTACU) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MedTech Acquisition's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-5.72 * ( 1 - -4.52% )	/	( (23.234	+	15.407)	/ 2 )
=	-5.978544	/	19.3205
=	-30.94 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	20.52	-	1.649	-	( 0.137	-	max(0, 4.664	-	0.301	+	0.137	))
=	23.234

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12.238	-	2.701	-	( 0.104	-	max(0, 6.031	-	0.161	+	0.104	))
=	15.407

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

MedTech Acquisition's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-5.72	/	( ( (0 + max(-1.485, 0))	+	(0 + max(-2.643, 0)) )	/	2 )
=	-5.72	/	( ( 0	+	0 )	/	2 )
=	-5.72	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.164)	-	(1.649	+	0	+	0)
=	-1.485

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.057)	-	(2.701	+	0	+	-0.0010000000000003)
=	-2.643

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

MedTech Acquisition's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-1.43	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

MedTech Acquisition Operating Income Related Terms

Thank you for viewing the detailed overview of MedTech Acquisition's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

MedTech Acquisition (MedTech Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » MedTech Acquisition Corp (NAS:MTACU) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

48 Maple Avenue, Greenwich, CT, USA, 06830

Website

MedTech Acquisition Corp is a blank check company.

Executives

Magnetar Financial Llc	10 percent owner	1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Magnetar Capital Partners Lp	10 percent owner	1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Supernova Management Llc	10 percent owner	1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David J. Snyderman	10 percent owner	C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David L Treadwell	director	222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102
Manuel Aguero	director	600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Thierry B. Thaure	director	3957 POINT EDEN WAY, HAYWARD CA 94545
David J Matlin	director, 10 percent owner, officer: Chief Financial Officer
Karim Karti	director	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Christopher C Dewey	director, 10 percent owner, officer: Chief Executive Officer	120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Robert H. Weiss	officer: Chief Admin Officer and Sec.	585 WEED STREET, NEW CANAAN CT 06840
Maurice R Ferre	director	C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317
Ivan Delevic	director	C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317
Medtech Acquisition Sponsor Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Martin William Roche	director	600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022